Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 57 articles: HTML format Text format

Single Articles

January 2012
1. RUTTEN MJ , Gaarenstroom KN, Van Gorp T, van Meurs HS, et al
   Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.
   BMC Cancer. 2012;12:31.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. LENHARD M , Tsvilina A, Schumacher L, Kupka M, et al
   Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.
   BMC Cancer. 2012;12:2.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
3. EICHBAUM M , Mayer C, Eickhoff R, Bischofs E, et al
   The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
   BMC Cancer. 2011;11:453.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. GAO Y , Liu Z, Chen X, Luo W, et al
   Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
   BMC Cancer. 2011;11:439.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
5. SERNBO S , Gustavsson E, Brennan DJ, Gallagher WM, et al
   The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
   BMC Cancer. 2011;11:405.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. XIA X , Ma Q, Li X, Ji T, et al
   Cytoplasmic p21 is a Potential Predictor for Cisplatin Sensitivity in Ovarian Cancer.
   BMC Cancer. 2011;11:399.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. NEWTON MJ , Hayes SC, Janda M, Webb PM, et al
   Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study.
   BMC Cancer. 2011;11:389.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   July 2011
8. NOSKE A , Schwabe M, Weichert W, Darb-Esfahani S, et al
   An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.
   BMC Cancer. 2011;11:294.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. SHARMA R , Graham J, Blagden S, Gabra H, et al
   Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer.
   BMC Cancer. 2011;11:289.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2011
10. CUI J , Miner BM, Eldredge JB, Warrenfeltz SW, et al
    Regulation of Gene Expression in Ovarian Cancer Cells by Luteinizing Hormone Receptor Expression and Activation.
    BMC Cancer. 2011;11:280.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. LU R , Sun M, Feng J, Gao X, et al
    Myofibrillogenesis Regulator 1 (MR-1) is a Novel Biomarker and Potential Therapeutic Target for Human ovarian cancer.
    BMC Cancer. 2011;11:270.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. S S , G S, K B, N V, et al
    Bilateral ovarian teratoma complicated with carcinosarcoma in a 68 year old woman: a case report.
    BMC Cancer. 2011;11:218.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
13. LEGGE F , Paglia A, D'asta M, Fuoco G, et al
    Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients.
    BMC Cancer. 2011;11:214.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. LANE D , Matte I, Rancourt C, Piche A, et al
    Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.
    BMC Cancer. 2011;11:210.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. DAVIS SJ , Choong DY, Ramakrishna M, Ryland GL, et al
    Analysis of the Mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
    BMC Cancer. 2011;11:173.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
16. BATRA J , Nagle CM, O'Mara T, Higgins M, et al
    A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.
    BMC Cancer. 2011;11:119.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
17. ESCREVENTE C , Keller S, Altevogt P, Costa J, et al
    Interaction and uptake of exosomes by ovarian cancer cells.
    BMC Cancer. 2011;11:108.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. MACHELON V , Gaudin F, Camilleri S, Nasreddine S, et al
    CXCL12 expression by healthy and malignant ovarian epithelial cells.
    BMC Cancer. 2011;11:97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
19. ROCHET N , Kieser M, Sterzing F, Krause S, et al
    Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study.
    BMC Cancer. 2011;11:41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. YUAN X , Lin X, Manorek G, Howell SB, et al
    Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
    BMC Cancer. 2011;11:61.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. SINGH PP , Joshi S, Russell PJ, Nair S, et al
    Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
    BMC Cancer. 2011;11:368.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
22. HORVATH G , Andersson H, Paulsson G
    Characteristic odour in the blood reveals ovarian carcinoma.
    BMC Cancer. 2010;10:643.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. HAMIDOU Z , Causeret S, Dabakuyo TS, Gentil J, et al
    Population-based study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years.
    BMC Cancer. 2010;10:622.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. YE S , Hao X, Zhou T, Wu M, et al
    Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
    BMC Cancer. 2010;10:611.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
25. HUANG L , Liao LM, Wang HY, Zheng M, et al
    Clinicopathologic characteristics and prognostic factors of ovarian fibrosarcoma: the results of a multi-center retrospective study.
    BMC Cancer. 2010;10:585.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. KIM YS , Do JH, Bae S, Bae DH, et al
    Identification of differentially expressed genes using annealing control primer system in stage III serous ovarian carcinoma.
    BMC Cancer. 2010;10:576.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. SCHROPFER A , Kammerer U, Kapp M, Dietl J, et al
    Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.
    BMC Cancer. 2010;10:553.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
28. NYKOPP TK , Rilla K, Tammi MI, Tammi RH, et al
    Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.
    BMC Cancer. 2010;10:512.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. BYRNE JA , Maleki S, Hardy JR, Gloss BS, et al
    MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    BMC Cancer. 2010;10:497.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. PRADHAN M , Risberg BA, Trope CG, van de Rijn M, et al
    Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    BMC Cancer. 2010;10:493.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
31. SU Y , Zheng L, Wang Q, Bao J, et al
    The PI3K/ Akt pathway upregulates Id1 and integrin alpha4 to enhance recruitment of human ovarian cancer endothelial progenitor cells.
    BMC Cancer. 2010;10:459.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
32. COCCO E , Casagrande F, Bellone S, Richter C, et al
    Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
    BMC Cancer. 2010;10:349.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
33. RAKHA S , Bayliss C, Sanderson F, Smith R, et al
    Pituitary hCG production and cerebral tuberculosis mimicking disease progression during chemotherapy for an advanced ovarian germ cell tumour.
    BMC Cancer. 2010;10:338.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. SEEBER LM , Horree N, van der Groep P, van der Wall E, et al
    Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.
    BMC Cancer. 2010;10:307.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
35. BERNARDINI MQ , Baba T, Lee PS, Barnett JC, et al
    Expression signatures of TP53 mutations in serous ovarian cancers.
    BMC Cancer. 2010;10:237.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BASSARAK N , Blankenstein T, Bruning A, Dian D, et al
    Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
    BMC Cancer. 2010;10:224.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. MEYNIEL JP , Cottu PH, Decraene C, Stern MH, et al
    A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.
    BMC Cancer. 2010;10:222.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. DAHL STEFFENSEN K , Waldstrom M, Kolby Christensen R, Bartels A, et al
    Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
    BMC Cancer. 2010;10:185.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
39. ZHANG S , Zhou X, Yu H, Yu Y, et al
    Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
    BMC Cancer. 2010;10:163.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. MAHNER S , Woelber L, Eulenburg C, Schwarz J, et al
    TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
    BMC Cancer. 2010;10:139.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. POLCHER M , Rudlowski C, Friedrichs N, Mielich M, et al
    In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
    BMC Cancer. 2010;10:137.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. YANG GF , He WP, Cai MY, He LR, et al
    Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.
    BMC Cancer. 2010;10:133.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. HE Y , Blackford JA Jr, Kohn EC, Simons SS Jr, et al
    STAMP alters the growth of transformed and ovarian cancer cells.
    BMC Cancer. 2010;10:128.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. BRENNAN DJ , Brandstedt J, Rexhepaj E, Foley M, et al
    Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
    BMC Cancer. 2010;10:125.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
45. MARTIROSYAN A , Clendening JW, Goard CA, Penn LZ, et al
    Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
    BMC Cancer. 2010;10:103.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. MORGAN R , Plowright L, Harrington KJ, Michael A, et al
    Targeting HOX and PBX transcription factors in ovarian cancer.
    BMC Cancer. 2010;10:89.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
47. KIM KK , Lange TS, Singh RK, Brard L, et al
    Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.
    BMC Cancer. 2010;10:72.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. KOTHANDARAMAN N , Bajic VB, Brendan PN, Huak CY, et al
    E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
    BMC Cancer. 2010;10:64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. SHEN J , Dicioccio R, Odunsi K, Lele SB, et al
    Novel genetic variants in miR-191 gene and familial ovarian cancer.
    BMC Cancer. 2010;10:47.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
50. NADIARNYKH O , Lacomb RB, Brewer MA, Campagnola PJ, et al
    Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy.
    BMC Cancer. 2010;10:94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. POURGHOLAMI MH , Cai ZY, Badar S, Wangoo K, et al
    Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
    BMC Cancer. 2010;10:143.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. DICKERSON EB , Blackburn WH, Smith MH, Kapa LB, et al
    Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.
    BMC Cancer. 2010;10:10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. OBERMAYR E , Sanchez-Cabo F, Tea MK, Singer CF, et al
    Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
    BMC Cancer. 2010;10:666.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2009
54. MAW MK , Fujimoto J, Tamaya T
    Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers.
    BMC Cancer. 2009;9:430.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. MCALPINE JN , Wiegand KC, Vang R, Ronnett BM, et al
    HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
    BMC Cancer. 2009;9:433.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2009
56. OSTERBERG L , Levan K, Partheen K, Delle U, et al
    Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
    BMC Cancer. 2009;9:368.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. UNGER FT , Klasen HA, Tchartchian G, de Wilde RL, et al
    DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.
    BMC Cancer. 2009;9:359.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: